Anthropic, the developer of Claude, has set up a wet biology laboratory in the San Francisco Bay Area, Reuters reported, citing two people familiar with the matter. Life-sciences head Eric Kauderer-Abrams confirmed the lab in an interview. A spokesperson later said the site is not specifically for drug discovery.

The laboratory moves some work from computer-only evaluations into physical experiments of the kind seen in biotechnology. The company says human oversight remains essential, including if AI models direct robotic equipment.

In June Anthropic announced a preclinical research programme focused on neglected diseases that traditional industry finds hard to finance. The September laboratory does not prove a new medicine and is not a clinical-trial unit.

Moving into physical experiments raises biosecurity questions. Access, monitoring and human validation matter precisely because the same tools can be misused.

Results will need independent publication and checks before any medical use. This article separates the existence of the lab from a clinical discovery.

The initiative remains an expansion of in-house research, not an announcement of a treatment.

The main source is Reuters’s 18 September account, not a detailed statement on diseases or molecules.

Image: pipetting in a biology lab / Wikimedia Commons. A generic laboratory, not Anthropic’s San Francisco site. Cropped to 16:9.

Source consulted: Anthropic quietly sets up biology lab as it ramps AI drug program | Reuters; Life sciences | Anthropic.